Financial Performance - Operating revenue for Q3 2024 was RMB 2,799,249,537.14, down 5.59% year-over-year, while year-to-date revenue was RMB 9,081,603,788.36, a decrease of 5.94%[2] - Net profit attributable to shareholders for Q3 2024 was RMB 501,763,106.12, an increase of 7.45% year-over-year, with year-to-date net profit at RMB 1,672,733,989.63, up 4.44%[2] - Basic earnings per share for Q3 2024 was RMB 0.54, reflecting an increase of 8.00% compared to the same period last year[2] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[6] - Operating profit increased to RMB 2,315,421,100.65, up 16.48% from RMB 1,987,239,809.53 year-on-year[17] - Net profit attributable to shareholders of the parent company reached RMB 1,672,733,989.63, representing a growth of 4.44% compared to RMB 1,601,554,878.96 in the previous year[17] - Total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 year-on-year[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 24,909,308,152.30, a decrease of 0.54% compared to the previous year-end[2] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59 at the end of the period[15] - The company's cash and cash equivalents decreased from RMB 11,325,723,855.76 to RMB 10,732,685,456.90[15] - The total non-current assets increased from RMB 7,778,652,409.47 to RMB 8,295,914,150.71[15] - Total liabilities decreased to RMB 9,973,518,408.08 from RMB 10,278,124,131.71, a reduction of 2.97%[16] - Current liabilities increased to RMB 9,013,265,318.62, up 11.43% from RMB 8,087,137,474.74 at the beginning of the year[16] - The company's total equity attributable to shareholders of the parent company rose to RMB 14,158,595,462.73, an increase from RMB 14,042,495,302.72[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was RMB 2,307,915,362.28, reflecting a growth of 4.32%[2] - Operating cash inflow for the period (January to September 2024) was RMB 10,217,108,238.70, a decrease of 5.2% from RMB 10,775,261,897.57 in the same period of 2023[19] - Net cash flow from operating activities increased to RMB 2,307,915,362.28, up 4.3% from RMB 2,212,403,355.39 year-on-year[19] - Cash inflow from financing activities increased to RMB 3,166,957,767.39, up 14.3% from RMB 2,770,410,168.70 in the previous year[20] - Net cash flow from financing activities was negative at RMB -1,912,251,596.10, worsening from RMB -1,768,301,850.08 year-on-year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes[8] - The largest shareholder, Hong Kong Central Clearing Limited, held 33.11% of the shares, amounting to 306,768,789 shares[8] - As of September 30, 2024, the company repurchased a total of 7,855,000 A-shares, accounting for 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[12] - The company repurchased 4,763,400 H-shares, with 2,778,800 shares canceled on June 28, 2024, representing 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[13] Other Financial Metrics - Financial expenses decreased by 74.63% to RMB -54.93 million, primarily due to reduced interest income and foreign exchange fluctuations[6] - Investment income fell by 48.98% to RMB 25.90 million, mainly due to changes in the profits of associated companies[6] - Research and development expenses were RMB 734,493,897.75, down 25.49% from RMB 985,755,413.94 in the same period last year[17] - Other comprehensive income after tax showed an improvement, with a net amount of RMB -49,894,257.61 compared to RMB -76,284,738.91 in the previous year[18] - The fair value change income was RMB -5.50 million, an improvement of 86.90% compared to RMB -41.99 million in the previous year, mainly due to fluctuations in the market value of securities investments[6]
丽珠医药(01513) - 2024 Q3 - 季度业绩